Navigation Links
Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
Date:7/9/2013

evalence of HCV infection is estimated to reach over 13 million people in the United States, EU, and Japan alone, of which only 13% are estimated to be diagnosed and treated.[1] In 2009, the total annual medical costs in the United States for people with hepatitis C are estimated to reach over $30 billion. In the next 20 years, total annual medical costs are expected to increase to approximately $85 billion.[2]

HCV is spread through direct contact with contaminated blood and ultimately leads to serious liver diseases, including liver damage, cirrhosis, liver failure or liver cancer which are all long term consequences of untreated chronic HCV infection.[3] Hepatitis C is the leading cause of liver transplantations in the United States and is reported to contribute to 15,000 deaths annually.[4],[5] With proper treatment, chronic hepatitis C can be cured; however, patients remain at an increased risk for progressive liver disease if they have not achieved complete viral clearance.[6],[7]

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. More information is available at <
'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Awarded Third Phase I STTR Grant
2. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
3. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
7. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
8. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 The nation,s newest Actos trial gets underway ... Vegas courtroom.  Attorneys representing two southern ... effects, including death, after using the diabetes drug Actos. ... a company knew, that their drug Actos caused an increased ... "In order to hold Takeda responsible it is appropriate to ...
(Date:8/27/2015)... HARRISBURG, Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular ... and second in the United States ... a new type of stent for blockages in the main ... flexibility within the artery and potentially less risk for stent ... MIMICS-2 is a prospective, single-arm, multicenter clinical trial of the ...
(Date:8/27/2015)... , Aug. 27, 2015  Lightwave Logic, Inc. ... development of Next Generation Photonic Devices and ... in high speed fiber-optic data communications and optical ... has been appointed to the Company,s Board ... the field of optoelectronics is widely recognized with ...
Breaking Medicine Technology:2 Billion Dollar Verdict Sought In Actos Trial 2First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3
... New Sites, BERKELEY HEIGHTS, N.J., Oct. 17 ... the French Health Products,Safety Agency ("AFSSAPS") has granted ... Genasense(R) (oblimersen sodium) Injection, its lead,anticancer compound, in ... of approximately 13 new investigative sites over the,next ...
... Venture Between Bristol-Myers Squibb, Company and ... HIV Treatment -, PRINCETON, N.J. and FOSTER ... (NYSE: BMY ) and Gilead Sciences, Inc.,(Nasdaq: ... has approved ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil ...
Cached Medicine Technology:Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency 2Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
(Date:8/28/2015)... ... 28, 2015 , ... Inc. magazine today ranked PREVENT Life Safety ... nation’s fastest-growing private companies. The list was unveiled online at Inc.com and is the ... last three years, PREVENT ranks higher on the list than any other company in ...
(Date:8/28/2015)... ... 28, 2015 , ... The Wilson and Juanita Mann Health ... improving a patient’s quality of life through early diagnosis and treatment. The focus ... diabetes, HIV/AIDS, STDs, and others. A Women’s, Infants & Children (WIC) clinic also ...
(Date:8/27/2015)... ... August 28, 2015 , ... This new webinar educates providers about how can ... for the next visit, their authorizations are in check, and they are current with ... Barnes, COO for Genesis Chiropractic Software, growing a practice depends on patient experience and ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... cost to treat a patient with hemophilia is $175,000. Hemophilia is an inherited, ... and improving treatment. The RMHBDA exists to help raise funds for patients suffering ...
(Date:8/27/2015)... ... ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. Mark Carney announced today that ... on Saturday, August 29, 2015 at the Marriott DTC, 4900 S. Syracuse Street, Denver, ... will present a two part seminar entitled, “How to Thrive as You Age & ...
Breaking Medicine News(10 mins):Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2Health News:Health Clinic Opening and Public Art Unveiling 2Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2
... discovered a potent and highly-debilitating toxin in the endangered ... now prompting investigations of other marine mammals in the ... marine algae common on coral reefs, and accumulates in ... human disease caused by ciguatoxin, affects thousands of people ...
... parental abuse as a child increases a person,s chances of ... research article in the current issue of the ... (Volume 66B, Number 3). An analysis of data ... early parental emotional abuse was associated with a higher number ...
... reports, lawsuits, congressional inquiries, claims and counterclaims, the question ... people lacks a definitive answer, according to a package ... edition of Chemical & Engineering News (C&EN), ACS,s weekly ... K. Ritter explains that BPA has been used in ...
... of nuclear stress tests, More women than men are ... studies ordered by primary care physicians ... Island and The Miriam hospitals suggests a possible gender ... tests, an imaging technique that measures blood flow to ...
... new generation of highly localized wireless networks that are ... from monitoring the functioning of implants, to tracking the ... But if this emerging technological area is to mature ... definition of its scope and potential, and a clearer ...
... ADDRESS SHORTAGE IN THE ICU , Intensive care ... worsen in the future. A recent study, conducted by ... Medical Center in New York, NY, studying 590 daytime ... non-physician providers can help address these staff shortages. ...
Cached Medicine News:Health News:Seniors abused during childhood face increased risk of sleep troubles 2Health News:Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals 2Health News:Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals 3Health News:The future of wireless body area networks is the focus of a June 19-20 workshop at WPI 2Health News:The future of wireless body area networks is the focus of a June 19-20 workshop at WPI 3Health News:Chest journal news briefs -- June 2011 issue 2
Near PT test card/4 1/2 to 12 PT in spanish & french /5 1/2" X 8....
Card has Jaeger rating and snellen equivalent....
Near point card 4 1/2 to 24 PT 5 1/2" x 8"....
... is specially designed to be a corrected Rosenbaum ... card (as noted by Horton and Jones in ... notations are not used because of the lack ... Wormington NP Card, the examiner can measure a ...
Medicine Products: